BACKGROUND: @entity4006 has been reported to achieve high rates of smoking cessation. It remains undetermined whether @entity4006 therapy improves vascular function in smokers. METHODS: Consecutive Seventy-two smokers (age 57    12 years) who succeeded in complete smoking cessation and 46 normal healthy volunteers (age 24    3 years) with no cardiovascular risk factors were enrolled into this study. Vascular function and structure were assessed by @entity384 ( @entity384 ), @entity1242 -induced vasodilation, and brachial artery intima-media thickness (baIMT) at baseline and 20 weeks after the initiation of @entity4006 therapy in smokers. @entity384 and baIMT were measured simultaneously using a semi-automatic vessel wall-tracking software program. 75  g dose of a @entity1242 tablet were sublingually administered for the @entity1242 -induced vasodilation measurement. RESULTS: Exhaled- @entity1223 concentration decreased significantly (20.0    11.1 ppm at baseline vs 1.9    1.5 ppm after 20 weeks, p < 0.001). @entity384 was significantly improved after 20 weeks (4.09%    1.83% at baseline vs 4.77%    2.33% after 20 weeks, p = 0.010), whereas @entity1242 -induced vasodilation and baIMT were not significantly changed. CONCLUSIONS: Smoking cessation with @entity4006 therapy significantly increased @entity384 without significant changes of @entity1242 -induced vasodilation or baIMT from baseline to 20 weeks. It appears to improve vascular function in smokers, which depends on endothelial function rather than on vascular smooth muscle function or changes in vascular structure.

Vascular Functional and Morphological Alterations in Smokers during XXXX Therapy.

@entity1223 :: ('MESH:D002248', 'Chemical') :: ['carbon monoxide'] @entity384 :: ('MESH:D002311', 'Disease') :: ['flow-mediated dilation', 'FMD'] @entity4006 :: ('MESH:C500838', 'Chemical') :: ['varenicline', 'Varenicline'] @entity1242 :: ('MESH:D005996', 'Chemical') :: ['nitroglycerin']
@entity4006 :: (MESH:C500838,Chemical) :: ['Varenicline']
